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The Journal of Immunology
PIKfyve, a Class III Lipid Kinase, Is Required for
TLR-Induced Type I IFN Production via Modulation of ATF3
Xinming Cai, Yongyao Xu, You-Me Kim,1 Joseph Loureiro, and Qian Huang
Type I IFN plays a key role in antiviral responses. It also has been shown that deregulation of type I IFN expression following
abnormal activation of TLRs contributes to the pathogenesis of systemic lupus erythematosus. In this study, we find that PIKfyve,
a class III lipid kinase, is required for endolysosomal TLR-induced expression of type I IFN in mouse and human cells. PIKfyve
binds to phosphatidylinositol 3-phosphate and synthesizes phosphatidylinositol 3,5-bisphosphate, and plays a critical role in endo-
lysosomal trafficking. However, PIKfyve modulates type I IFN production via mechanisms independent of receptor and ligand
trafficking in endolysosomes. Instead, pharmacological or genetic inactivation of PIKfyve rapidly induces expression of the tran-
scription repressor ATF3, which is necessary and sufficient for suppression of type I IFN expression by binding to its promoter and
blocking its transcription. Thus, we have uncovered a novel phosphoinositide-mediated regulatory mechanism that controls TLR-
mediated induction of type I IFN, which may provide a new therapeutic indication for the PIKfyve inhibitor. The Journal of
Immunology, 2014, 192: 3383–3389.
T
oll-like receptor signaling plays a critical role in the
innate immune response. TLR pathways are triggered by
pathogen-associated molecular patterns and coordinate
inflammatory and antipathogen responses (1). It is known that
dysregulated TLR signaling functions in a number of autoimmune
diseases primarily caused by dysregulation of cytokine production
(2). IFN-a, a member of the type I IFN family, induces many
clinical features of SLE. An important source of IFN-a in vivo
consists of plasmacytoid dendritic cells (pDCs) activated via
TLR7 and TLR9 (3, 4). Within the TLR family of proteins, TLR7
recognizes ssRNA of viral origin, whereas TLR9 is a sensor for
unmethylated CpG dinucleotides in viral and bacterial DNA.
These TLR7 and TLR9 ligands traffic through early endosomes
and are retained within endolysosomes. Newly synthesized TLR7
and TLR9 reside within the endoplasmic reticulum (ER) and are
delivered to endolysosomal compartments upon activation (5, 6).
This differential, activation-dependent receptor/ligand localization
helps coordinate a proper response to pathogen-derived compo-
nents yet avoids inappropriate responses to self-antigens. How-
ever, in lupus patients, immune complexes consisting of dsDNA
from apoptotic cells and antinucleotide IgG are taken up by pDCs.
This internalized immune complex activates the endosomal TLR7
and TLR9 pathway, leading to production of IFN-a and the pro-
gression of SLE (7).
PIKfyve is a class III lipid kinase that phosphorylates the D-5
position in endosomal phosphatidylinositol 3-phosphate [P1(3)P]
to yield phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2] (8).
Vac14 and Sac3 form a regulatory complex with PIKfyve. Both
Vac14 and Sac3 are required for maximal PIKfyve activity (9–11).
PIKfyve-mediated PI(3,5)P2 signaling has been shown to play a
critical role in multiple biological processes by regulating endo-
somal trafficking, such as GLUT4 translocation, retroviral bud-
ding (12, 13), autophagy (14), and neurodegeneration. Recently,
we revealed that PIKfyve is the molecular target of apilimod (15),
which is the first clinically evaluated small-molecule IL-12/IL-23
antagonist (16, 17). We have shown that apilimod specifically
binds to PIKfyve and inhibits its activity, which in turn silences
TLR-induced IL-12/IL-23 production.
In this study, we demonstrated that PIKfyve also has an im-
portant function in type I IFN production induced by TLR7/9.
Apilimod treatment blocks TLR7/9-induced type I IFN produc-
tion, as also observed in PIKfyve-deficient cells. However, the
inhibitory effect is not mediated by the known role of PIKfyve in
endosomal trafficking because TLR7/9 receptor and ligand traf-
ficking is not impaired. Instead, we elucidated the downstream
effector of PIKfyve in regulating type I IFN and IL-12p40 ex-
pression by inducing the expression of ATF3, thus unraveling the
mechanism of this lipid kinase in modulating TLR signaling.
Materials and Methods
Constructs and reagents
The retrovirus constructs encoding TLR9-GFP and lentivirus mCherry-
CD63 were made as previously described (6). pENTR-ATF3 (human)
was purchased from Invitrogen and subcloned into pcDNA6.2-DEST.
All the control and gene-specific short hairpin RNAs (shRNAs) used in
the study were ordered from Sigma-Aldrich MISSION shRNA collection.
The nontarget shRNA is the pLKO.1-puro Non-Mammalian shRNA
Control. This control contains a shRNA insert that does not target human
and mouse genes. Phospho-p38, p38, phospho-p65, p65 and IkBa Abs
were purchased from Cell Signaling Technology. ATF3 and IRAK1 Abs
were obtained from Santa Cruz Biotechnology. FITC-CD11c and PE-
B220 Abs were purchased from BD Pharmingen. Tubulin Ab was ob-
tained from Abcam.
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CpG and ssRNA were synthesized by Integrated DNA Technologies
using the following sequence: 59-UUGUUGUUGUUGUU-39 (poly-GU),
59-GUUCCAUUGGCUCUGGUGCUU-39 (STAT-2AS), 59-TCCATGAC-
GTTCCTGACGTT-39 (ODN1826), 59-GGGGGACGATCGTCGGGGGG-
39 (ODN2216), and 59-GGTGCATCGATGCAGGGGGG-39 (D19). Other
TLR ligands were purchased from Invivogen.
Human IFN-a and mouse IFN-a/IFN-b ELISA kits were purchased
from PBL. All other ELISA kits were obtained from R&D Systems. All
quantitative PCR (qPCR) probes were purchased from ABI.
Virus production and infection
Lentivirus shRNA was packaged in 293T cells via cotransfection of
pLP1, pLP2, and pLP/VSVG. Retrovirus was packaged in 293T cells via
cotransfection of Gag-Pol and VSVG. RAW264.7 cells were infected with
supernatant containing virus plus polybrene (final concentration, 8 mg/ml;
Sigma-Aldrich) overnight. The stable cell lines were maintained in medium
containing puromycin (6 mg/ml) or G418 (400 mg/ml).
Cell culture
RAW264.7 and 293T cells were purchased from American Type Culture
Collection and maintained under standard conditions described in the
American Type Culture Collection instructions. Human PBMCs were
isolated using Ficoll (GE Health). Human pDCs were enriched from CD3+-
depleted PBMCs. Mouse pDCs were differentiated from mouse bone marrow
cells, using Flt3L as previously described (18). pDC differentiation was con-
firmed by CD11c and B220 staining.
Mouse breeding
Mouse strains Vac14,ingls. and C57 BL/6 were purchased from The
Jackson Laboratory. All mice were maintained according to Novartis
Institutes for BioMedical Research animal guidelines.
Genome-wide gene expression analysis
Genome-wide gene expression analysis was performed as previously de-
scribed (19). Briefly, RAW264.7 cells were treated with TLR ligand and
compound. Cells were harvested at 0, 1, 3, 7, and 22 h. Total RNA was
isolated and hybridized to mouse oligonucleotide arrays (Affymetrix). Data
were collected and analyzed using Spotfire. Microarray datasets have been
deposited into the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE22124) under accession number GSE22124.
Intracellular pH measurement
The intracellular pHmeasurement was performed as described (20). Briefly,
RAW264.7 cells were seeded into eight-well cover glass-bottom chambers
(Lab-Tek) overnight. Cells were incubated with the LysoSensor Yellow/
Blue dextran (1 mg/ml, Invitrogen) for 14 h and then washed with cold
PBS. For the standard curve, medium was changed to pH standard buffer
with 10 mM monensin and 20 mM nigericin. For the tested samples, me-
dium was changed to assay medium (phenol red–free DMEM; 5% FBS; 25
mM HEPES, pH7.4) and incubated with compound for 60 min. Images
were captured by Zeiss LSM510, using Plan-Apochromat 363/1.4 oil
differential interference contrast lens. The Yellow/Blue ratio images were
processed and quantified with MetaXpress software. The standard curve
was plotted according to the image ratio. The pH of lysosome in compound-
treated cells was calculated based on the standard curve.
CpG uptake
The CpG uptake assay was performed as previously described (21).
Live cell imaging
For live cell imaging, cells were seeded into a P35 glass-bottomdish (MatTek)
(4 3 105 cells per dish) and maintained in phenol red–free DMEM sup-
plemented with 5% FBS and 25 mM HEPES (pH 7.4) at 37˚C in an envi-
ronment chamber. Images were acquired using a Zeiss LSM510 confocal
microscope with a Plan-Apochromat 363/1.4 oil differential interference
contrast lens. Zeiss LSM Image Browser was used for imaging analysis.
Luciferase reporter assay
293T cells were seeded on 24-well plates for 16 h and transiently transfected
with 50 ng firefly luciferase reporter plasmid, 1 ng Renilla luciferase
plasmid, and 70 ng total of various expression vectors. The firefly and
Renilla luciferase activities were measured using Dual-Glo Luciferase
Assay System (Promega). The Renilla luciferase activity was used as an
internal control for normalization.
Chromatin immunoprecipitation assay
RAW264.7 cells were cross-linked by 1% formaldehyde, and chromatin
immunoprecipitation (ChIP) assay was performed according to the man-
ufacturer’s protocol (Millipore). A total of 10 mg ATF3 Abs (Santa Cruz
Biotechnology) was used for immunoprecipitation. The purified DNA,
after reverse cross-linking, was analyzed by real-time PCR, using primers
specific for the promoters of IFN-b.
Sequences of promoter-specific primers: IFN-b, sense: 59-GAGCT-
ATGGCCCATTGATGT-39; anti-sense: 59-GCTGCTGCCCTTTGAAA-
TAG-39.
qPCR
For qPCR assay, mRNAs were isolated using the TurboCapture 96 mRNA
Kit (QIAGEN). cDNAs were synthesized using the ABI High Capacity
cDNA Reverse Transcription Kit. TaqMan Gene Expression Assays were
performed using the ABI 7900HT Fast Real-Time PCR System. All data
were normalized to b-actin.
Results
Inactivation of PIKfyve by apilimod selectively inhibits
TLR-induced expression of type I IFN
Apilimod is the first clinically evaluated low m.w. IL-12/IL-23
antagonist that selectively blocks TLR-induced IL-12/IL-23 (16).
Recently, we identified PIKfyve as the molecular target of apili-
mod in the antagonism of IL-12/IL-23 production (15). Apilimod
is shown to be a potent and highly selective PIKfyve inhibitor. It
has an IC50 of 14 nM against PIKfyve kinase in vitro without any
activity toward other lipid kinases (15). Because PIKfyve is a key
regulator of endosomal integrity, we decided to investigate its role
in endosomal TLR signaling. We used global gene expression
analysis in RAW264.7 cells treated with or without apilimod
and stimulated with TLR7 agonist R848. Of interest, we found
apilimod blocked the expression of only a subset of cytokines,
which includes IFN-b, a member of the type I IFN family
(GSE22124). This result was confirmed by both qPCR and ELISA
assay (Fig. 1A). Moreover, apilimod also blocks TLR3- and
TLR9-induced expression of IFN-b in RAW264.7 cells (Fig. 1B).
The other type I IFN family member, IFN-a, is exclusively pro-
duced by TLR7/TLR9-stimulated pDCs. We found apilimod also
blocked TLR9-induced production of IFN-a/b in mouse Flt3L
pDCs and TLR7/TLR9-induced production of IFN-a in human
pDCs (Fig. 1C, 1D). Although apilimod inhibited the expression
of type I IFN, it did not inhibit TLR-induced TNF-a in mouse
cells and IL-8 production in human pDCs (Fig. 1A, 1C, 1D).
Apilimod thus selectively inhibits the expression of type I IFN
across multiple endosomal TLR pathways.
To confirm that apilimod blocks production of type I IFN by
inactivation of PIKfyve, we used the spontaneous mutant mouse,
ingls, which carries a missense mutation in PIKfyve adaptor
Vac14 (L156R) (9). The Ingls mutation interrupts the interaction
of PIKfyve with Vac14, which abolishes the kinase activity of
PIKfyve and reduces the level of PI(3,5)P2. Indeed, the expression
of both IFN-a and IFN-b was abolished following TLR9 activa-
tion in pDCs derived from Vac14ingls/ingls mice (Fig. 1E). These
data suggest that PIKfyve is required for TLR-induced IFN-a
production.
PIKfyve modulates the expression of TLR-induced type I IFN
via mechanisms independent of receptor and ligand trafficking
Although PIKfyve is required for TLR-induced expression of type I
IFN, the molecular mechanism is unknown. It has been shown that
all type I IFN–inducing TLRs signal from the endolysosome (22).
We hypothesized that intracellular TLR/ligand interaction may
be compromised by PIKfyve inactivation because PIKfyve and
its product PI(3,5P)2 are regulators of endolysosome membrane
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traffic (23); that is, inhibition of PIKfyve could affect endosomal
pH or cause a defect in ligand or receptor translocation in endo-
lysosomes.
To investigate the role of PIKfyve in endolysosome acidification,
we measured the endolysosome pH using LysoSensor, a pH in-
dicator exhibiting a pH-dependent fluorescence change. Although
bafilomycin, an inhibitor of vacuolar-type H+ ATPase, neutralized
the endolysosomal pH, inactivation of PIKfyve by apilimod did
not block endolysosomal acidification in RAW264.7 cells even
at a concentration as high as 1 mM (Fig. 2A). Subsequently, we
studied the effect of PIKfyve inhibition on intracellular trafficking
of TLR9 and its ligand (CpG). Inhibition of PIKfyve did not
disrupt CpG-induced endolysosomal localization of TLR9-GFP
(Fig. 2B, Supplemental Fig. 1A, 1B), as a majority of TLR-GFP
colocalized with endolysosomal marker (mCherry-CD63), but not
ER marker (ER-mCherry), in the presence of apilimod. Inactiva-
tion of PIKfyve therefore does not disrupt ER–endolysosomal
trafficking of TLR9. Moreover, we tested CpG uptake, using flow
cytometry. PIKfyve inhibition had no effect on CpG uptake by
cells (Fig. 2C). We also did not observe a major defect in CpG
trafficking to endolysosomes in apilimod-treated cells, except a
slight delay at the early stage, which did not lead to the inhibition
of TNF-a production (Fig. 1A, Supplemental Fig. 1C).
Furthermore, intracellular distribution of a TLR7 agonist R848
over endolysosomes was not disrupted in the presence of apilimod
(Fig. 2D; TLR9-GFP was used as a surrogate TLR7 marker be-
cause TLR7-GFP could not be visualized in living cells). Of note,
R848 accumulation appeared to increase in endolysosomes, which
is consistent with increased activation of NF-kB and p38 upon
apilimod treatment, as well as enhanced expression of TNF-a in
RAW264.7 cells (Fig. 1A, 2E). Therefore, it appears that inacti-
vation of PIKfyve lipid kinase activity selectively inhibits the
expression of type I IFN by mechanism(s) independent of ligand/
receptor trafficking.
Inactivation of PIKfyve induces expression of the transcription
repressor ATF3
To explore the underlying mechanism of PIKfyve-dependent
control of cytokine expression, we used global gene expression
analysis. We focused on R848 stimulation, as we did not observe
any defect of its accumulation in endolysosomes. It appears that
newly synthesized protein(s) might be required for the PIKfyve
inactivation–mediated cytokine silencing effect, because R848-
induced late responsive genes are more sensitive to apilimod
treatment (Fig. 3A and GSE22124). Indeed, cycloheximide, an
inhibitor of protein biosynthesis, blocked the apilimod-mediated
silencing and rescued production of IFN-b (Fig. 3B). A known
transcriptional repressor for TLR-induced IL-12p40, ATF3 was
among the most strongly upregulated genes in response to apili-
mod and R848 stimulation (Fig. 3C and GSE22124) (24, 25). Both
FIGURE 1. PIKfyve is required for TLR-induced type I IFN production. The production of cytokines was measured by ELISA following overnight
stimulation. mRNAs were collected after 1 h of stimulation for determination of TNF-a and 4 h of stimulation for determination of IFN-b by qPCR. (A and
B) RAW264.7 cells were treated with the indicated dose of apilimod in the presence of R848 (0.1 mM), polyinosinic-polycytidylic acid (100 mg/ml), or
CpG (ODN1826, 5 mM). All bar graphs of IFN-b production were analyzed using one-way ANOVA (p, 0.001), indicating a significant effect of apilimod
on the production of IFN-b. (C) Mouse Flt3L DCs were treated with the indicated dose of apilimod in the presence of CpG (D19, 5 mM). (D) Human pDCs
were treated with the indicated dose of apilimod in the presence of ssRNA (poly-GU, 20 mg/ml, and packaged with DOTAP) or CpG (ODN2216, 5 mM).
All bar graphs were analyzed using one-way ANOVA (p , 0.0001), indicating a significant effect of apilimod on the production of type I IFN. (E) Flt3L
DCs from wild-type (WT) or ingls mice (n = 3) were challenged with type A CpG (D19, 5 mM) for 24 h. Representative results from experiments using
three matched WT/ingls pairs. *p , 0.05 using Student t test. Data with error bars represent mean 6 SD.
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ATF3 mRNA and protein expression were greatly induced by
apilimod in RAW264.7 cells (Fig. 3D and Supplemental Fig. 2A,
2B), as well as in Flt3L DCs treated with apilimod or Flt3L DCs
isolated from Vac14 mutant mice (Fig. 3E, 3F). Our data suggest
that ATF3 is specifically induced upon inactivation of PIKfyve.
PIKfyve inhibitor silences cytokine production by induction of
ATF3
Next, we set out to examine whether the induction of ATF3 by
PIKfyve inactivation plays a role in the effect of apilimod on
cytokine expression. Although repression of TLR-induced IL-12p40
production by ATF3 has been reported (24, 25), its effect on type I
IFN expression is unknown. To determine the role of ATF3 in this
process, we established an IRF7-dependent IFN-b promoter re-
porter system in 293T cells. Overexpression of ATF3 suppressed
IRF7-driven IFN-b promoter activation in a dose-dependent
manner (Fig. 4A). In contrast, MyD88-driven activation of the
NF-kB–dependent ELAM promoter was intact when cells were
cotransfected with ATF3. ATF3 may thus function as a specific
repressor of the IFN-b promoter. In addition, silencing of ATF3
also rescued the inhibitory effect of apilimod on R848-induced
expression of IFN-b but had little effect on induction of TNF-a
by R848 (Fig. 4B, 4C). PIKfyve inactivation may thus selectively
inhibit IFN-b expression via induction of ATF3. Furthermore,
FIGURE 2. PIKfyve modulates the expression of TLR-mediated type I IFN via mechanisms independent of receptor and ligand trafficking. (A) In-
tracellular pH measurement: RAW264.7 cells were incubated with LysoSensor Yellow/Blue dextran and treated with bafilomycin (0.1 mM) or apilimod
(0.1 mM or 1 mM). The yellow channel was displayed as a red color. The pH measurement is derived from the Yellow/Blue ratio. (B) RAW264.7 cells stably
expressing TLR9-GFP and mCherry-CD63 were treated with DMSO or apilimod (100 nM) in the presence of CpG (ODN1826, 5 mM) for 60 min. Scale
bar, 5 mm. Cells were imaged using Zeiss LSM510 confocal microscopy with a 363 lens. (C) RAW264.7 cells were treated with DMSO or apilimod at the
indicated temperature and fed with FITC-CpG (ODN1826, 2 mM) for 30 min. Trypan blue was added to quench the exogenous FITC-CpG for 5 min. Cells
were washed three times with PBS. The internalized CpG was measured by flow cytometry. Data with error bars represent mean6 SD. (D) RAW264.7 cells
stably expressing TLR9-GFP (surrogate TLR7 marker) were treated with DMSO or apilimod (100 nM) in the presence of TAMRA-R848 (5 mM) for
120 min. Cells were washed once before imaging. Scale bar, 5 mm. Cells were imaged using Zeiss LSM510 confocal microscopy with a 363 lens. (E)
RAW264.7 cells were pretreated with DMSO or apilimod (100 nM) for an hour and then stimulated with R848 (0.1 mM). Cells were lysed at the indicated
times and blotted with the indicated Abs. Representative results from two independent experiments.
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knockdown of ATF3 antagonized the inhibitory effect of apilimod
on expression of IL-12p40 in THP-1 cells (Supplemental Fig. 3),
which also confirms that ATF3 is required for PIKfyve-mediated
IL-12p40 expression. Therefore, inactivation of PIKfyve promotes
ATF3 expression and potentiates ATF3-mediated silencing of a
subset of cytokine expression.
To gain mechanistic insights into ATF3-dependent regulation of
cytokine expression mediated by PIKfyve inactivation, we ex-
amined the binding of ATF3 to the promoter of IFN-b upon R848
stimulation in the presence or absence of apilimod by ChIP. As
shown in Fig. 4D, R848-induced ATF3 was recruited to the IFN-b
promoter, suggesting ATF3 might play a negative regulatory role
in IFN-b expression, as observed with IL-12p40 (24, 25). Of in-
terest, significantly more ATF3 bound to the IFN-b promoter
when cells were treated with apilimod. These data confirm that
PIKfyve inactivation regulates the expression of IFN-b via ATF3
modulation. In summary, apilimod enhances TLR-induced ATF3
expression and promotes occupancy of ATF3 on the IFN-b pro-
moter, and in turn silences its expression.
Discussion
In this study, we demonstrated that PIKfyve is required for
endosomal TLR-induced type I IFN production. Surprisingly,
despite the induction of massive vacuoles from endosome/lysosome
origin in cells when PIKfyve is inactivated, TLR7/TLR9 receptor
and ligand trafficking and activation in endolysomes appear to be
normal. This unexpected finding led to the discovery of a mecha-
nism by which PIKfyve exerts its cellular function via induction of
the transcription repressor ATF3. Moreover, we uncovered a pre-
viously unknown function of ATF3 in regulating type I IFN ex-
pression. Our results thus suggest a new druggable node for selective
regulation of TLR-induced type I IFN expression, and in turn,
provide opportunities for pharmacological intervention in IFN-a–
mediated diseases.
Human IFN-a is exclusively produced by pDCs following ac-
tivation of endolysosomal TLR7/TLR9. Although IFN-a plays
a critical role in antiviral responses, multiple lines of evidence
suggest that abnormal upregulation of IFN-a contributes to the
progression of SLE. To date, a number of approaches are being
evaluated in the clinic by targeting IFN-a, including the admin-
istration of anti–IFN-a Ab in lupus patients (26). Besides bio-
logical therapy, an orally available selective small-molecule IFN-a
antagonist will be highly desirable. In our study, we found that
apilimod, a clinically evaluated PIKfyve antagonist, selectively
blocks TLR7/TLR9-induced IFN-a in pDCs. This approach pro-
vides an advantage over the IFN-a Ab by blocking the IFN-a
FIGURE 3. Inactivation of PIKfyve induces expression of the transcription repressor ATF3. (A) Analysis of global gene expression in RAW264.7 cells
challenged with R848 (0.1 mM) in the presence of apilimod (1 mM) at the indicated times. Upregulated genes were defined as the gene whose induction over
DMSO control$2-fold. (B) RAW264.7 cells were pretreated with cycloheximide (20 mg/ml) or DMSO for 30 min before being incubated with the indicated
dose of apilimod and R848 (0.1 mM). The mRNAs were collected at 4 h for qPCR assay. *p , 0.1, **p , 0.01. (C) Kinetics of ATF3 mRNA expression in
RAW264.7 cells treated with apilimod (1 mM) or API09 (15) (1 mM, inactive analog of apilimod) in the presence of R848 (0.1 mM). (D) RAW264.7 cells
were treated with apilimod (1 mM) and R848 (0.1 mM) for 4 h. Cells were lysed and blotted with indicated Abs. (E) Flt3L DCs were treated with DMSO or
apilimod (1 mM) and stimulated with R848 (10 mM). mRNAs were collected at the indicated times for qPCR. *p , 0.1. (F) Flt3L DCs from wild-type or
ingls mice were challenged with R848 (10 mM). mRNAs were collected at 4 h for qPCR. **p , 0.01. Data with error bars represent mean 6 SD.
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pathway relevant to disease progression. Therefore, these results
shed light on a novel approach for SLE treatment.
Despite the induction of vacuoles, trafficking and activation
of TLR7/TLR9 receptors and their reported ligands appear to
be normal. The PIKfyve inhibitor only slightly delays the CpG
trafficking from early endosomes to endolysosomes, but does not
block ligand–receptor interaction in endolysosomes at later stages
in RAW264.7 cells. It has been reported that CpG uptake is im-
paired in RAW264.7 cells that express the VPS34 kinase–dead
mutant (27). VPS34 is a class III PI3K that phosphorylates the D-3
position on PI to yield PI(3)P. PI(3)P and PI(3,5)P2 might thus
regulate distinct steps of intracellular trafficking of CpG. CpG
could use an alternative trafficking route independent of MVB,
as supported by the observation that CpG could still reach the
endolysosomal compartment at a later stage in the presence of
PIKfyve inhibitors.
TLR9 translocates normally to endolysosomes, despite the en-
largement of both endosomes and lysosomes when PIKfyve ac-
tivity is inhibited. Although PIKfyve is required for retrograde
trafficking from lysosomes to the trans–Golgi network (28), its
activity may not be required for the cargo trafficking from the
trans–Golgi network to endolysosomes, as proposed for translo-
cation of TLR9 from the ER (29).
Importantly, using apilimod as a tool, we shed light on the in-
tracellular trafficking of R848, a small-molecule TLR7/TLR8
pathway activator. We showed that R848 was localized to endo-
lysosomes in live cells and that its trafficking is PIKfyve inde-
pendent. More R848 accumulates within endolysosomes in the
presence of apilimod (Fig. 2D), possibly owing to the enlarged size
of endolysosomes or defects of exit, which might explain the in-
crease of TNF-a production following overnight treatment with
apilimod (Fig. 1A) and sustained activation of signaling events
downstream of TLR7 (Fig. 2E). R848 might enter the cell in
a clathrin-independent manner, via interaction with other protein(s)
or accumulation in acidic endolysosomes as a weak base. Our
results therefore suggest further specialization in the endolysosomal
handling of the nucleic acid–sensing TLR to an extent greater than
has been appreciated until now.
How can an endosomal lipid kinase modulate the activation of
only a subset of cytokines downstream of TLR7 and TLR9? Al-
though apilimod reportedly inhibited IL-12p40 expression by
blocking translocation of c-Rel to the nucleus (30), we failed to
detect this defect in IFN-g/LPS stimulated THP-1 cells in the
presence of apilimod (Supplemental Fig. 4). Subsequently, we
identify the induction of ATF3 as the mechanism by which PIKfyve
inhibitors exert their endocytosis-independent function and selec-
tively inhibit IL-12p40 and type I IFN expression. Apilimod treat-
ment strongly enhanced expression of ATF3 in response to TLR
engagement and amplified the ATF3-mediated adaptive gene–si-
lencing mechanism. Although ATF3 might be induced by Ca2+
imbalance in the ER (31), we did not observe any signs of ER stress
induced upon apilimod treatment, determined by analysis of the
activation of all three branches of the unfolded protein response
(data not shown). Therefore, it is unlikely that ATF3 is induced by a
systemic stress response. Instead, an imbalance of PI(3)P/PI(3,5)P2
in endolysosomal membranes induced by inactivation of PIKfyve
may trigger activation of an unknown endolysosomal lipid sensor,
which leads to a specific induction of ATF3.
In summary, we uncover a new role for PIKfyve in selectively
regulating TLR-induced type I IFN. Of interest, TLR7/TLR9 re-
FIGURE 4. PIKfyve inhibitor silences IFN-b
production by induction of ATF3. (A) 293T cells
were transfected with a reporter plasmid contain-
ing IFN-b or ELAM promoter and other indicated
plasmids for 48 h. The reporter activation was
measured by a Dual-Glo Luciferase Assay. The
results were normalized with those from Renilla
luciferase. p , 0.001 for the IFN-b promoter
results by one-way ANOVA. (B) RAW264.7 cells
stably expressing the indicated shRNAs were
treated with increasing doses of apilimod in the
presence or absence of R848 (0.1 mM). Cell
supernatants were collected following 18 h of
stimulation for ELISA. *p, 0.05, **p, 0.01. (C)
RAW264.7 cells stably expressing nontarget or
ATF3 shRNAs were treated with R848 (0.1 mM)
and apilimod (100 nM). Cells were lysed at 4 h
and blotted with the indicated Abs. (D) RAW264.7
cells were treated with DMSO or apilimod (1 mM)
and stimulated with R848 (0.1 mM) for 4 h. Re-
cruitment of ATF3 to the indicated promoters was
measured by ChIP assay. *p , 0.1, indicating a
significant difference on the recruitment of ATF3
between R848- and R848/apilimod-treated sam-
ples. Data with error bars represent mean 6 SD.
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ceptor and ligand trafficking and activation in endolysomes appear
to be normal when PIKfyve is inactivated. This finding led to the
discovery of a mechanism by which PIKfyve exerts its novel
cellular function via induction of a transcriptional repressor ATF3.
Our study thus couples a specific phosphoinositide composition in
endolysosomes with a negative feedback loop in TLR signaling.
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